USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony
SALT LAKE CITY, April 1, 2025 /CNW/ -- USANA Health Sciences (NYSE: USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being.
While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress.
A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has the extraordinary ability to uplift and inspire, and I encourage everyone to immerse themselves in the joy of playing guitar this month. It's a simple, powerful way to enhance your well-being."
Because playing guitar nurtures both mind and soul, Guest reveals six ways it boosts mental well-being.
Stress Escape: Anyone can lose themselves in music and find calm in the strums.
Boosted Mood: Playing guitar releases dopamine, the happiness chemical.
Mindfulness: Focusing on music reduces anxiety and centers one's mind.
Social Connection: Sharing music builds powerful, emotional bonds.
Creative Outlet: Songwriting expresses emotions and eases stress.
Better Sleep: Relaxing guitar sessions lead to improved rest.
In his bestselling book, "All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony," Guest emphasizes how music minimizes stress and strengthens relationships that matter, "When I was young, I lived music down to my bones, and harmonies played constantly in my head. I wanted to be a rock star more than anything else.
"Today, music speaks to the soul like nothing else can. This love for music, this awe I have for the process, has been with for me as long as I can remember. Music has transformed my life and offered calmness and clarity where there was chaos. When anxiety takes hold, a melody actually soothes my nerves. Whether it's a soft tune or a lively rhythm with bands I play in, music brings a peace I never thought possible. It's been my strength, saving me more times than I can count."
More inspiring examples of the power of the power of music are shared throughout All the Right Reasons, where all proceeds go to feeding hungry children. Each book purchase provides 40 meals. For more information, visit www.kevinguest.com.
USANA Health Sciences (NYSE: USNA), a global leader in health and wellness products, has long recognized the importance of social wellness in building a successful business. From its founding in 1992, USANA has focused on clear and concise communication to build trust with its customers and distributors in 25 countries. For more information about USANA Health Sciences and its dedication to promoting health, wellness, and entrepreneurial success, visit USANA.com.
MEDIA CONTACT: Tim Brown, Candid Communications tim@candidcom.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/usana-exec-chairman-kevin-guest-celebrates-guitar-month-stress-awareness-month-for-harmony-302416134.html
SOURCE USANA
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/01/c3583.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs. NUMELVI, a once-daily, first-line treatment, will be the only second-generation Janus kinase (JAK) inhibitor indicated for the treatment of pruritus associated with allergic dermatitis including atopic dermatitis and treatment of clinical manifestations of atopic dermatitis in dogs, upon full approval by the European Commission. NUMELVI inhibits the function of JAK1-dependent cytokines involved in itch and inflammation in allergic and atopic dermatitis and is at least 10-fold more selective for JAK1 compared to the other JAK family members (JAK2, JAK3 and TYK2). JAK1 selectivity minimizes interference with cytokines involved in hematopoiesis and immune functions dependent on the other JAKs, resulting in a compelling safety profile with proven efficacy in dogs and puppies. Once approved, it will be the only JAK inhibitor that can be used in dogs as young as six months of age. With a once-daily treatment regimen, NUMELVI is clinically effective after the first dose. Treatment with NUMELVI had no impact on immune response to vaccination. "Merck Animal Health has been committed to bringing innovation to our customers aimed at rapidly controlling and treating a common condition that causes distress for so many pets and pet owners," said Rick DeLuca, executive vice president and president, Merck Animal Health. "With today's positive opinion for NUMELVI, we are one step closer to making this novel, highly selective JAK inhibitor available." Itch is seen in more than 20 percent of dogs in general veterinary practice and is one of the most frequent reasons for veterinary visits. As allergic dermatitis progresses, quality of life in dogs declines and the relationship between a pet and its owner can be weakened due to emotional distress, interruptions in sleep and routines, increased expenses, and time lost to provide treatment and veterinary follow-up to manage an itchy dog. Veterinarians also face challenges in managing dogs with allergic dermatitis, as diagnosis and treatment takes time and requires regular progress checks. "Merck Animal Health continues to deliver cutting-edge innovation and science with first- and best-in-class veterinary medicinal products that address important unmet needs," said Holger Lehmann, DVM, PhD, vice present and global head, research and development for pharmaceuticals, Merck Animal Health. "NUMELVI not only offers a once-daily dosing regimen but also features a distinctive safety profile that permits its use in dogs as young as six months. Additionally, a vaccine response study has shown that NUMELVI does not affect the immune response to core vaccinations." Based on the CVMP's recommendation, the European Commission is expected to issue a decision for marketing authorization in the European Union (EU) during the third quarter of 2025. About Merck Animal Health At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( View source version on Contacts Media:Kim Gorode973-255-8094ahglobalmedia@ Investor:Peter
Business Wire
6 hours ago
- Business Wire
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs. NUMELVI, a once-daily, first-line treatment, will be the only second-generation Janus kinase (JAK) inhibitor indicated for the treatment of pruritus associated with allergic dermatitis including atopic dermatitis and treatment of clinical manifestations of atopic dermatitis in dogs, upon full approval by the European Commission. NUMELVI inhibits the function of JAK1-dependent cytokines involved in itch and inflammation in allergic and atopic dermatitis and is at least 10-fold more selective for JAK1 compared to the other JAK family members (JAK2, JAK3 and TYK2). JAK1 selectivity minimizes interference with cytokines involved in hematopoiesis and immune functions dependent on the other JAKs, resulting in a compelling safety profile with proven efficacy in dogs and puppies. Once approved, it will be the only JAK inhibitor that can be used in dogs as young as six months of age. With a once-daily treatment regimen, NUMELVI is clinically effective after the first dose. Treatment with NUMELVI had no impact on immune response to vaccination. 'Merck Animal Health has been committed to bringing innovation to our customers aimed at rapidly controlling and treating a common condition that causes distress for so many pets and pet owners,' said Rick DeLuca, executive vice president and president, Merck Animal Health. 'With today's positive opinion for NUMELVI, we are one step closer to making this novel, highly selective JAK inhibitor available.' Itch is seen in more than 20 percent of dogs in general veterinary practice and is one of the most frequent reasons for veterinary visits. As allergic dermatitis progresses, quality of life in dogs declines and the relationship between a pet and its owner can be weakened due to emotional distress, interruptions in sleep and routines, increased expenses, and time lost to provide treatment and veterinary follow-up to manage an itchy dog. Veterinarians also face challenges in managing dogs with allergic dermatitis, as diagnosis and treatment takes time and requires regular progress checks. 'Merck Animal Health continues to deliver cutting-edge innovation and science with first- and best-in-class veterinary medicinal products that address important unmet needs,' said Holger Lehmann, DVM, PhD, vice present and global head, research and development for pharmaceuticals, Merck Animal Health. 'NUMELVI not only offers a once-daily dosing regimen but also features a distinctive safety profile that permits its use in dogs as young as six months. Additionally, a vaccine response study has shown that NUMELVI does not affect the immune response to core vaccinations.' Based on the CVMP's recommendation, the European Commission is expected to issue a decision for marketing authorization in the European Union (EU) during the third quarter of 2025. About Merck Animal Health At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals ®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
Yahoo
9 hours ago
- Yahoo
CANADA DAY 2025 IN PIERREFONDS-ROXBORO: THE EVENT OF THE YEAR!
PIERREFONDS-ROXBORO, QC, June 12, 2025 /CNW/ - The Borough of Pierrefonds-Roxboro is proud to unveil the official program for Canada Day 2025 — a festive and unmissable celebration that brings together thousands of residents of all ages every year. Whether you're with family or friends, young or young at heart, the July 1st festivities are designed to unite the entire community in a warm, joyful, and inclusive atmosphere. "Canada Day is always a cherished time in Pierrefonds-Roxboro, and this year, we're especially excited to welcome Simple Plan, an iconic hometown band that has conquered the global stage. Their presence promises an unforgettable show for our residents and highlights the scale of this year's celebration. I'm incredibly proud of their journey and success — especially since they're local boys!" — Dimitrios (Jim) Beis, Mayor of Pierrefonds-Roxboro JUNE 27 TO JULY 1: A FULL WEEK OF FUN FOR EVERYONE Colorful rides, a lively parade, delicious street food, high-energy music, and a spectacular fireworks show — everything you need for unforgettable memories! Amusement Park – June 27 to July 1Located on the grounds of Pierrefonds Comprehensive High and coupons available online and at on-site ticket booths. Ride Schedule: Friday, June 27: 4 p.m. to 11 p.m. Saturday, June 28: 12 p.m. to 11 p.m. Sunday, June 29: 12 p.m. to 10 p.m. Monday, June 30: 12 p.m. to 10 p.m. Tuesday, July 1: 12 p.m. to 10 p.m. Canada Day Parade – July 1A festive and colorful event for all ages! Start: 10 a.m. from École de l'Altitude (5060 Sources Blvd.) End: Between 11:30 a.m. and 12 p.m. at Pierrefonds Comprehensive High School (13800 Pierrefonds Blvd.) JULY 1, EVENING: SIMPLE PLAN LIVE ON STAGE! As part of their highly anticipated world tour, Simple Plan will make a special stop in Pierrefonds-Roxboro — a true homecoming for the iconic West Island band that has inspired generations while staying true to their Canadian roots. Don't miss this once-in-a-lifetime chance to experience a "Summer Paradise" during a spectacular event! Main Stage – Free Admission 6:00 p.m.: Site opens 6:00 p.m. – 10:00 p.m.: Street food trucks (fees apply) 8:30 p.m. – 10:00 p.m.: Live concert by Simple Plan, Montreal's internationally renowned pop-rock legends 10:00 p.m. – 10:15 p.m.: Spectacular fireworks show 10:30 p.m.: Event closes A COMMUNITY CELEBRATION OF OUR CANADIAN PRIDEJoin us for the biggest party of the year in Pierrefonds-Roxboro! Enjoy music, entertainment, good vibes, and unforgettable moments as we come together to celebrate what unites us as Canadians. Be part of the magic and help make Canada Day 2025 a summer highlight! SPECIAL NOTE ABOUT NATIONAL HOLIDAY CELEBRATIONS In a spirit of collaboration and complementarity, the boroughs of Pierrefonds-Roxboro and L'Île-Bizard–Sainte-Geneviève have entered into an agreement whereby each takes the lead in organizing one of the two major national celebrations. Pierrefonds-Roxboro is responsible for Canada Day festivities, while L'Île-Bizard–Sainte-Geneviève hosts the Saint-Jean-Baptiste celebrations. This partnership allows both boroughs to offer high-quality events to all residents, while proudly showcasing each holiday. Each borough warmly invites residents from the other to take part in the festivities — celebrating together in a spirit of unity and shared pride. Follow the communications issued by the borough's Administration on its website, Facebook page, it's Instagram page and newsletter, as well as on Ville de Montréal's digital billboards. SOURCE Ville de Montréal - Borough of Pierrefonds-Roxboro View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
